Parathyroid Hormone
2014; Lippincott Williams & Wilkins; Volume: 34; Issue: 7 Linguagem: Inglês
10.1161/atvbaha.114.303637
ISSN1524-4636
AutoresClaudia Goettsch, Hiroshi Iwata, Elena Aïkawa,
Tópico(s)Bone health and treatments
ResumoHomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 34, No. 7Parathyroid Hormone Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBParathyroid HormoneCritical Bridge Between Bone Metabolism and Cardiovascular Disease Claudia Goettsch, Hiroshi Iwata and Elena Aikawa Claudia GoettschClaudia Goettsch From the Center for Interdisciplinary Cardiovascular Sciences (C.G., H.I., E.A.) and Center for Excellence in Vascular Biology (E.A.), Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. , Hiroshi IwataHiroshi Iwata From the Center for Interdisciplinary Cardiovascular Sciences (C.G., H.I., E.A.) and Center for Excellence in Vascular Biology (E.A.), Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. and Elena AikawaElena Aikawa From the Center for Interdisciplinary Cardiovascular Sciences (C.G., H.I., E.A.) and Center for Excellence in Vascular Biology (E.A.), Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Originally published1 Jul 2014https://doi.org/10.1161/ATVBAHA.114.303637Arteriosclerosis, Thrombosis, and Vascular Biology. 2014;34:1333–1335Parathyroid hormone (PTH) is a principal regulator of calcium balance in physiological and pathological conditions associated with cardiovascular disorders and plays a major physiological role in bone homeostasis (Figure 1). PTH systemically controls bone remodeling by modulating the bone marrow microenvironment and regulating osteogenic signaling pathways.1 PTH and its related peptide can have both anabolic and catabolic effects. Although intermittent administration of PTH is osteoanabolic and antiosteoporotic via stimulation of bone formation, its continuous administration may cause catabolic osteoporotic changes. Experimental studies showed that intermittent injection of full length PTH (PTH1–84) or its N-terminal fragment (PTH1–34) increases bone formation with normal microarchitecture by coupling bone remodeling1 as well as promoting bone vascular structure and function.2 Clinically, intermittent administration of PTH is an established osteoanabolic therapy that improves quality of life in patients with severe osteoporosis.3 However, potential adverse effects by long-term use of PTH have not been fully elucidated.Download figureDownload PowerPointFigure 1. Parathyroid hormone (PTH) as a novel mediator of bone–vascular–renal interaction. Cardiovascular disorders include but are not limited to valvular and vascular calcification, atherosclerosis (inflammation), and hypertension.See accompanying article on page 1567The presence of PTH receptors within the cardiovascular system,4 including vasculature (smooth muscle cells, endothelial cells) and heart (cardiomyocytes), suggests that secreted PTH may play a role in the pathophysiology of cardiovascular diseases beyond its role in mineral and bone metabolism (Figure 2).Download figureDownload PowerPointFigure 2. Hypothetical signaling pathways of parathyroid hormone (PTH) receptor in cardiovascular disorders based on previously published reports. cAMP indicates cyclic adenosine monophosphate; C-PTH, carboxyl-terminal PTH; dotted arrows, postulated but unknown pathways; ECs, endothelial cells; ERK, extracellular signal-regulated kinase; FGF23, fibroblast growth factor 23; Ox PTH, oxidized PTH; PKA, protein kinase A; PKC, protein kinase C; PLC, phospholipase C; PTH1,2R, PTH 1,2 receptor; PTHrP, PTH-related peptide; solid arrows, previously reported pathways; and VSMCs, vascular smooth muscle cells.Clinically, patients with primary hyperparathyroidism have a higher risk of cardiovascular mortality and have a broad spectrum of adverse cardiovascular disorders such as coronary microvascular dysfunction, subclinical aortic valve calcification, increased aortic stiffness, endothelial dysfunction, and hypertension.5 Furthermore, secondary hyperparathyroidism, the most significant complication in patients with chronic kidney disease, causes abnormal bone disorders as well as extraskeletal calcification, such as vascular and valvular calcification, and increased risk of cardiovascular mortality.6 Moreover, recent observational studies indicate that high PTH is an important novel cardiovascular risk factor with powerful predictive value for cardiovascular disease and mortality in individuals even without hyperparathyroidism.7In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Hagström et al8 highlighted PTH as a strong risk predictor for clinical and subclinical atherosclerotic disease using 2 Swedish community-based populations with >1000 70-year-old individuals. The first cohort (PIVUS [Prospective Investigation of the Vasculature in Uppsala Seniors] study) revealed that intact PTH is independently associated with the burden of atherosclerosis, even after adjustment to vascular risk factors and mineral metabolism variables. In a second independent cohort (USLAM [Uppsala Longitudinal Study of Adult Men] study) with a follow-up of 16.7 years, PTH was associated with increased long-term risk of nonfatal atherosclerotic disease in peripheral and large vessels and accounted for 11.6% of the population attributable risk proportion. These findings are consistent with previously published studies. In a prospective study of healthy individuals (n=476), serum PTH levels were positively associated with the number of stenotic coronary arteries.9 Further, PTH is associated with increased risk of cardiovascular events in patients with stage 3/4 chronic kidney disease independent of calcium-phosphate levels.10 The Multi-Ethnic Study of Atherosclerosis also demonstrated the association among PTH and hypertension, and a tripartite association among PTH, carotid stiffness, and systolic blood pressure, thus providing new evidence for the role of PTH in cardiovascular diseases.11,12Recent studies have indicated a protective effect of PTH lowering by cinecalcet on cardiovascular disorders, including the reduction of abdominal aortic calcification13 and arterial stiffness,14 whereas reduction in cardiovascular morbidity and mortality in patients on hemodialysis with complications attributable to hyperparathyroidism was not detected. The association between long-term exposure of high PTH and vascular15 and valvular calcification16 has been demonstrated mainly in patients with renal dysfunction.Given its elevated expression in chronic kidney disease patients, these findings suggest that cardiovascular calcification might be the key link between PTH and atherosclerosis. Nevertheless, there have been several experimental studies challenging this hypothesis. PTH1–34 has been shown to reduce vascular calcification in vitro and in vivo17 by suppressing vascular BMP2-Msx2-Wnt signaling.18 Like PTH1–34, PTH-related peptide suppresses the expression of osteogenic markers and calcium deposition in smooth muscle cells.19 Conversely, the PTH1R antagonist PTH-related peptide7–34 enhances alkaline phosphatase expression and calcium deposition in vitro.19It is important to mention that most of these experimental studies were performed using the N-terminal fragment of PTH, whereas clinical studies measure intact PTH, indicating that mechanistic studies may not reflect the clinical situation. Moreover, emerging evidence indicates that modifications of PTH alter its biological function. The carboxyl-terminal PTH fragment, which represents 70% to 95% of circulating PTH, exerts specific effects on calcium homeostasis and bone metabolism, opposite to those of the synthetic agonist of PTH/PTH-related peptide receptor,20 suggesting that carboxyl-terminal PTH may promote vascular calcification. Also, in patients requiring dialysis, a certain proportion of circulating PTH is oxidized and thus loses its PTH receptor–stimulating properties but remains detectable by immunoassay.21 Therefore, current PTH assay systems may inadequately reflect PTH-related cardiovascular abnormalities in patients on chronic hemodialysis. Indeed, in a diabetic rat model with metabolic disorder and elevated oxidative stress, the positive bone anabolic effects of PTH were blunted,22 suggesting that conditions with high oxidative stress modify PTH. Indeed, a recent clinical study revealed that the mortality in hemodialysis patients was associated with oxidized PTH but not with nonoxidized PTH levels.23 It is intriguing to speculate that oxidative stress, a well-established risk factor for cardiovascular diseases, might be an important missing link for the association between PTH and atherosclerotic disease. Oxidized PTH is likely to be increased with age, which in turn associates with accelerated oxidative stress. For the evaluation of PTH as a cardiovascular risk factor, it is necessary to assess the biological function and importance of PTH subtypes (eg, oxidized PTH, carboxyl-terminal PTH) that may differ from the most studied PTH forms (PTH1–34, PTH1–84) and thereby introduce different clinical implications, including cardiovascular calcification.Changes in mineral metabolism as well as interactive cross talk between the skeletal system and cardiovascular system play a crucial role in vascular disorders such as atherosclerosis or vascular calcification. Although the relationship between osteoporosis and vascular calcification has long been known as the calcification paradox, the key players in this process still remain unclear. Many studies have highlighted an important role for the RANK/RANKL/OPG (receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand/osteoprotegerin) axis in skeletal and extraskeletal calcification.24 PTH could be a potential candidate to add to the list of mediators of the bone–vascular interaction.The ultimate clinical goal in the field is to establish a therapy for preventing bone loss without increasing the risk for cardiovascular disorders. In the present study, Hagström et al8 showed that the highest quartile of PTH (>5.27 pmol/L) in the cohort was associated with the degree of atherosclerosis and increased risk of nonfatal atherosclerotic disorders. Considering the causal role of PTH in atherosclerosis as suggested above, a possible cardiovascular intervention for patients might be the lowering of specific subtypes of PTH that do not affect bone metabolism. In addition, visualizing of extraskeletal calcification25 and correlation of calcium scores with PTH levels in the future clinical trials would help answering many key questions. Taken together, PTH may provide not only critical information about bone disease but also offer novel preventive measures and therapeutic insights into patients' cardiovascular health.AcknowledgementsWe thank Joshua D. Hutcheson, PhD, for editorial assistance.Sources of FundingDr Aikawa is supported by grants from the National Institutes of Health (R01HL114805; R01HL109506).DisclosuresNone.FootnotesCorrespondence to Elena Aikawa, MD, PhD, Brigham and Women's Hospital, Harvard Medical School, 77 Ave Louis Pasteur, Boston, MA 02115. E-mail [email protected]References1. Crane JL, Cao X. Bone marrow mesenchymal stem cells and tgf-beta signaling in bone remodeling.J Clin Invest. 2014; 124:466–472.CrossrefMedlineGoogle Scholar2. Roche B, Vanden-Bossche A, Malaval L, Vico L, Normand M, Jannot M, Chaux R, Lafage-Proust MH. Parathyroid hormone 1–84 targets bone vascular structure and perfusion in mice: impacts of its administration regimen and of ovariectomy [published online ahead of print 2014].J Bone Miner Res. doi:10.1002/jbmr.2191. http://onlinelibrary.wiley.com/doi/10.1002/jbmr.2191/abstract;jsessionid=88820FA682FCC4604CC1A7F2A0EDACA8.f03t01. Accessed May 22, 2014.Google Scholar3. Baron R, Hesse E. Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives.J Clin Endocrinol Metab. 2012; 97:311–325.CrossrefMedlineGoogle Scholar4. Clemens TL, Cormier S, Eichinger A, Endlich K, Fiaschi-Taesch N, Fischer E, Friedman PA, Karaplis AC, Massfelder T, Rossert J, Schlüter KD, Silve C, Stewart AF, Takane K, Helwig JJ. Parathyroid hormone-related protein and its receptors: nuclear functions and roles in the renal and cardiovascular systems, the placental trophoblasts and the pancreatic islets.Br J Pharmacol. 2001; 134:1113–1136.CrossrefMedlineGoogle Scholar5. Macfarlane DP, Yu N, Leese GP. Subclinical and asymptomatic parathyroid disease: implications of emerging data.Lancet Diabetes Endocrinol. 2013; 1:329–340.CrossrefMedlineGoogle Scholar6. Silver J, Naveh-Many T. FGF-23 and secondary hyperparathyroidism in chronic kidney disease.Nat Rev Nephrol. 2013; 9:641–649.CrossrefMedlineGoogle Scholar7. Hagström E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundström J, Melhus H, Held C, Lind L, Michaëlsson K, Arnlöv J. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community.Circulation. 2009; 119:2765–2771.LinkGoogle Scholar8. Hagström E, Michaëlsson K, Melhus H, Hansen T, Ahlström H, Johansson L, Ingelsson E, Sundström J, Lind L, Ärnlöv J. Plasma–parathyroid hormone is associated with subclinical and clinical atherosclerotic disease in 2 community-based cohorts.Arterioscler Thromb Vasc Biol. 2014; 34:1567–1573.LinkGoogle Scholar9. Shekarkhar S, Foroughi M, Moatamedi M, Gachkar L. The association of serum parathyroid hormone and severity of coronary artery diseases.Coron Artery Dis. 2014; 25:339–342.CrossrefMedlineGoogle Scholar10. Lishmanov A, Dorairajan S, Pak Y, Chaudhary K, Chockalingam A. Elevated serum parathyroid hormone is a cardiovascular risk factor in moderate chronic kidney disease.Int Urol Nephrol. 2012; 44:541–547.CrossrefMedlineGoogle Scholar11. Blondon M, Sachs M, Hoofnagle AN, Ix JH, Michos ED, Korcarz C, Gepner AD, Siscovick DS, Kaufman JD, Stein JH, Kestenbaum B, de Boer IH. 25-Hydroxyvitamin D and parathyroid hormone are not associated with carotid intima-media thickness or plaque in the multi-ethnic study of atherosclerosis.Arterioscler Thromb Vasc Biol. 2013; 33:2639–2645.LinkGoogle Scholar12. Gepner AD, Colangelo LA, Blondon M, Korcarz CE, de Boer IH, Kestenbaum B, Siscovick DS, Kaufman JD, Liu K, Stein JH. 25-hydroxyvitamin d and parathyroid hormone levels do not predict changes in carotid arterial stiffness: the multi-ethnic study of atherosclerosis.Arterioscler Thromb Vasc Biol. 2014; 34:1102–1109.LinkGoogle Scholar13. Nakayama K, Nakao K, Takatori Y, Inoue J, Kojo S, Akagi S, Fukushima M, Wada J, Makino H. Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism.Int J Nephrol Renovasc Dis. 2013; 7:25–33.MedlineGoogle Scholar14. Bonet J, Bayés B, Fernández-Crespo P, Casals M, López-Ayerbe J, Romero R. Cinacalcet may reduce arterial stiffness in patients with chronic renal disease and secondary hyperparathyroidism - results of a small-scale, prospective, observational study.Clin Nephrol. 2011; 75:181–187.CrossrefMedlineGoogle Scholar15. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J; ADVANCE Study Group. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.Nephrol Dial Transplant. 2011; 26:1327–1339.CrossrefMedlineGoogle Scholar16. Linefsky JP, O'Brien KD, Katz R, de Boer IH, Barasch E, Jenny NS, Siscovick DS, Kestenbaum B. Association of serum phosphate levels with aortic valve sclerosis and annular calcification: the cardiovascular health study.J Am Coll Cardiol. 2011; 58:291–297.CrossrefMedlineGoogle Scholar17. Shao JS, Cheng SL, Charlton-Kachigian N, Loewy AP, Towler DA. Teriparatide (human parathyroid hormone (1–34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice.The Journal of biological chemistry. 2003; 278:50195–50202CrossrefMedlineGoogle Scholar18. Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals.J Clin Invest. 2005; 115:1210–1220.CrossrefMedlineGoogle Scholar19. Cheng SL, Shao JS, Halstead LR, Distelhorst K, Sierra O, Towler DA. Activation of vascular smooth muscle parathyroid hormone receptor inhibits Wnt/beta-catenin signaling and aortic fibrosis in diabetic arteriosclerosis.Circ Res. 2010; 107:271–282.LinkGoogle Scholar20. Scillitani A, Guarnieri V, Battista C, Chiodini I, Salcuni AS, Minisola S, Francucci CM, Carnevale V. Carboxyl-terminal parathyroid hormone fragments: biologic effects.J Endocrinol Invest. 2011; 34(7 suppl):23–26.MedlineGoogle Scholar21. Hocher B, Armbruster FP, Stoeva S, Reichetzeder C, Grön HJ, Lieker I, Khadzhynov D, Slowinski T, Roth HJ. Measuring parathyroid hormone (PTH) in patients with oxidative stress–do we need a fourth generation parathyroid hormone assay?PLoS One. 2012; 7:e40242.CrossrefMedlineGoogle Scholar22. Hamann C, Picke AK, Campbell GM, Balyura M, Rauner M, Bernhardt R, Huber G, Morlock MM, Günther KP, Bornstein SR, Glüer CC, Ludwig B, Hofbauer LC. Effects of parathyroid hormone on bone mass, bone strength, and bone regeneration in male rats with type 2 diabetes mellitus.Endocrinology. 2014; 155:1197–1206.CrossrefMedlineGoogle Scholar23. Tepel M, Armbruster FP, Grön HJ, Scholze A, Reichetzeder C, Roth HJ, Hocher B. Nonoxidized, biologically active parathyroid hormone determines mortality in hemodialysis patients.J Clin Endocrinol Metab. 2013; 98:4744–4751.CrossrefMedlineGoogle Scholar24. Hofbauer LC, Brueck CC, Shanahan CM, Schoppet M, Dobnig H. Vascular calcification and osteoporosis–from clinical observation towards molecular understanding.Osteoporos Int. 2007; 18:251–259.CrossrefMedlineGoogle Scholar25. Hjortnaes J, New SE, Aikawa E. Visualizing novel concepts of cardiovascular calcification.Trends Cardiovasc Med. 2013; 23:71–79.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Kim J, Byun J, Kim J, Park M, Hong S, Nam T, Choi H, Hong S, Han S, Jeong H, Park K and Kim H (2021) Analysis of microRNA signatures in ischemic stroke thrombus, Journal of NeuroInterventional Surgery, 10.1136/neurintsurg-2021-017597, 14:5, (469-474), Online publication date: 1-May-2022. Malla P, Liao H, Liu C and Wu W (2021) Electrochemical immunoassay for serum parathyroid hormone using screen-printed carbon electrode and magnetic beads, Journal of Electroanalytical Chemistry, 10.1016/j.jelechem.2021.115463, 895, (115463), Online publication date: 1-Aug-2021. Menez S, Ding N, Grams M, Lutsey P, Heiss G, Folsom A, Selvin E, Coresh J, Jaar B and Matsushita K (2020) Serum magnesium, bone–mineral metabolism markers and their interactions with kidney function on subsequent risk of peripheral artery disease: the Atherosclerosis Risk in Communities Study, Nephrology Dialysis Transplantation, 10.1093/ndt/gfaa029, 35:11, (1878-1885), Online publication date: 1-Nov-2020. Kim J, Lee W and Kim J (2020) Therapeutic strategy for atherosclerosis based on bone-vascular axis hypothesis, Pharmacology & Therapeutics, 10.1016/j.pharmthera.2019.107436, 206, (107436), Online publication date: 1-Feb-2020. Ma J, Qiao L, Meng L, Ma L, Zhao Y, Liu X, Ni M and Zhang Y (2019) Tongxinluo may stabilize atherosclerotic plaque via multiple mechanisms scanning by genechip, Biomedicine & Pharmacotherapy, 10.1016/j.biopha.2019.108767, 113, (108767), Online publication date: 1-May-2019. Gong L, Tang W, Lu J and Xu W (2019) Thermal ablation versus parathyroidectomy for secondary hyperparathyroidism: A meta-analysis, International Journal of Surgery, 10.1016/j.ijsu.2019.08.004, 70, (13-18), Online publication date: 1-Oct-2019. DeLuccia R, Cheung M, Ramadoss R, Aljahdali A and Sukumar D (2019) The Endocrine Role of Bone in Cardiometabolic Health, Current Nutrition Reports, 10.1007/s13668-019-00286-0, 8:3, (281-294), Online publication date: 1-Sep-2019. Cheung M, DeLuccia R, Ramadoss R, Aljahdali A, Volpe S, Shewokis P and Sukumar D (2019) Low dietary magnesium intake alters vitamin D—parathyroid hormone relationship in adults who are overweight or obese, Nutrition Research, 10.1016/j.nutres.2019.08.003, 69, (82-93), Online publication date: 1-Sep-2019. Fujii H (2018) Association between Parathyroid Hormone and Cardiovascular Disease, Therapeutic Apheresis and Dialysis, 10.1111/1744-9987.12679, 22:3, (236-241), Online publication date: 1-Jun-2018. Malyszko J, Koc-Zorawska E, Kozminski P, Matuszkiewicz-Rowinska J and Malyszko J (2018) Underrecognition and Underestimation of Disturbances in Calcium-Phosphate Balance in Kidney Transplant Recipients, Transplantation Proceedings, 10.1016/j.transproceed.2018.02.155, 50:6, (1790-1793), Online publication date: 1-Jul-2018. Çelik G, Doğan A, Dener Ş, Öztürk Ş, Kulaksızoğlu S and Ekmekçi H (2017) Parathyroid Hormone Levels in the Prediction of Ischemic Stroke Risk, Disease Markers, 10.1155/2017/4343171, 2017, (1-8), . Watanabe H, Sugimoto R, Ikegami K, Enoki Y, Imafuku T, Fujimura R, Bi J, Nishida K, Sakaguchi Y, Murata M, Maeda H, Hirata K, Jingami S, Ishima Y, Tanaka M, Matsushita K, Komaba H, Fukagawa M, Otagiri M and Maruyama T (2017) Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-κB signaling pathway in secondary hyperparathyroidism, Biochemical Pharmacology, 10.1016/j.bcp.2017.08.016, 145, (192-201), Online publication date: 1-Dec-2017. Colón-Emeric C (2016) Osteoporosis as a Geriatric Syndrome Osteoporosis in Older Persons, 10.1007/978-3-319-25976-5_7, (131-140), . Verdoia M, Pergolini P, Rolla R, Nardin M, Barbieri L, Schaffer A, Bellomo G, Marino P, Suryapranata H and De Luca G (2016) Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor, Cardiovascular Therapeutics, 10.1111/1755-5922.12188, 34:4, (209-215), Online publication date: 1-Aug-2016. Cho H, Lee S, Shin J, Moon S, Han J, Cha B and Kim E (2016) Association of serum calcium concentrations with fibrinogen and homocysteine in nondiabetic Korean subjects, Medicine, 10.1097/MD.0000000000003899, 95:24, (e3899), Online publication date: 1-Jun-2016. Park J, Choi S, Rhee Y, Chung J, Choi E and Kim D (2015) Parathyroid Hormone, Calcium, and Sodium Bridging Between Osteoporosis and Hypertension in Postmenopausal Korean Women, Calcified Tissue International, 10.1007/s00223-015-9972-x, 96:5, (417-429), Online publication date: 1-May-2015. Campos-Obando N, Kavousi M, Roeters van Lennep J, Rivadeneira F, Hofman A, Uitterlinden A, Franco O and Zillikens M (2015) Bone health and coronary artery calcification: The Rotterdam Study, Atherosclerosis, 10.1016/j.atherosclerosis.2015.02.013, 241:1, (278-283), Online publication date: 1-Jul-2015. Pugliese G, Iacobini C, Fantauzzi C and Menini S (2015) The dark and bright side of atherosclerotic calcification, Atherosclerosis, 10.1016/j.atherosclerosis.2014.12.011, 238:2, (220-230), Online publication date: 1-Feb-2015. Schurgers L, Akbulut A, Kaczor D, Halder M, Koenen R and Kramann R (2018) Initiation and Propagation of Vascular Calcification Is Regulated by a Concert of Platelet- and Smooth Muscle Cell-Derived Extracellular Vesicles, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2018.00036, 5 Bakhshian Nik A, Ng H, Garcia Russo M, Iacoviello F, Shearing P, Bertazzo S and Hutcheson J (2022) The Time-Dependent Role of Bisphosphonates on Atherosclerotic Plaque Calcification, Journal of Cardiovascular Development and Disease, 10.3390/jcdd9060168, 9:6, (168) Cheng Z, Ye T, Ling Q, Wu T, Wu G and Zong G (2017) Parathyroid hormone promotes osteoblastic differentiation of endothelial cells via the extracellular signal‑regulated protein kinase 1/2 and nuclear factor‑κB signaling pathways, Experimental and Therapeutic Medicine, 10.3892/etm.2017.5545 Zawierucha J, Malyszko J, Malyszko J, Prystacki T, Marcinkowski W and Dryl-Rydzynska T (2019) Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study—A Comparison, Frontiers in Endocrinology, 10.3389/fendo.2019.00040, 10 July 2014Vol 34, Issue 7 Advertisement Article InformationMetrics © 2014 American Heart Association, Inc.https://doi.org/10.1161/ATVBAHA.114.303637PMID: 24951650 Originally publishedJuly 1, 2014 KeywordsinflammationbonecalcificationatherosclerosiscardiovascularPDF download Advertisement
Referência(s)